Follow The Filings

AMRX Amneal Pharmaceuticals

Health Care, filed as AMNEAL PHARMACEUTICALS CL A ORD (EQUITY), Equity Among managers we track Quote on Google Finance, opens in a new tab

No current holdings among managers we track for this security. See ownership history or the ownership grid, activity, or search.

Insider trades

Open-market buys and sales by AMRX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All AMRX insider trades
  • None no insider bought on the open market
  • $9.8M sold by 5 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. John Kiely Director
    Sale
    $882K 50,000 shares at $17.64 19% of stake
    Traded Aug 13 Filed Aug 14
    ↗
  2. Nikita Shah Executive Vice President
    Sale
    $2.6M 146,403 shares at $17.51 37% of stake
    Traded Aug 12 Filed Aug 13
    ↗
  3. Jason B. Daly EVP, Chief Legal Officer
    Sale
    $3.8M 216,613 shares at $17.41 86% of stake
    Traded Aug 11–12 Filed Aug 13
    ↗
  4. Deborah M. Autor Director
    Sale
    $451K 34,819 shares at $12.94 27% of stake
    Traded May 11 Filed May 12
    ↗
  5. Ted C Nark Director
    Sale
    $586K 50,000 shares at $11.72 15% of stake
    Traded Nov 17, 2025 Filed Nov 19, 2025
    ↗
  6. Nikita Shah Executive Vice President
    Sale
    $1.6M 131,856 shares at $11.92 47% of stake
    Traded Nov 12, 2025 Filed Nov 14, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 38 option exercises, 26 share withholdings for taxes, 4 stock grants, and 4 gifts.

SEC filings

Recent issuer filings from EDGAR, 19 shown.

Filed Form Detail Links
8-K/A 9.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 1.01,2.01,2.03,3.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 1.01 Filing Doc
8-K 5.07 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
DEFA14A Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.07 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
DEFA14A Filing Doc
DEFA14A Filing Doc
DEFA14A Filing Doc
DEFA14A Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated 7 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $2.39B $2.79B $3.02B
Gross profit $0.821B $1.02B $1.11B
Gross margin * 34.3% 36.5% 36.9%
Net income -$79.26M — $72.06M
Net margin * -3.3% — 2.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $1.38B $1.59B $1.91B
Total non-current assets * $2.09B $1.91B $1.77B
Total assets $3.47B $3.5B $3.68B
Total current liabilities $0.847B $1.13B $0.882B
Total non-current liabilities $2.56B $2.42B $2.79B
Total equity $19.78M -$109.27M -$70.79M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $345.58M $295.1M $339.99M
Cash from investing -$69.19M -$63M -$112.26M
Cash from financing -$212.57M -$211.79M -$31.53M
Net change in cash $63.88M $19.31M $194.52M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.